{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "STRONTIUM CHLORIDE Sr-89",
      "indication": "INDICATIONS AND USAGE STRONTIUM CHLORIDE Sr-89 INJECTION, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.",
      "manufacturer": "Q BioMed Inc",
      "splSetId": "c89bcf16-399d-48e0-a4e3-849261aaa310"
    }
  ],
  "id": "Strontium_Chloride_Sr-89",
  "nciThesaurus": {
    "casRegistry": "38270-90-5",
    "chebiId": "",
    "chemicalFormula": "2Cl.Sr",
    "definition": "The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain.",
    "fdaUniiCode": "5R78837D4A",
    "identifier": "C1238",
    "preferredName": "Strontium Chloride Sr-89",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1446"
    ],
    "synonyms": [
      "Metastron",
      "STRONTIUM CHLORIDE SR-89",
      "Strontium Chloride Sr-89",
      "strontium chloride Sr 89"
    ]
  }
}